封面
市场调查报告书
商品编码
1169177

表观遗传学药物和诊断技术市场:按类型(表观遗传学药物,(DNMT抑製剂、HDAC抑製剂,其他),表观遗传学诊断技术),地区规模,份额,前景,机会分析2022-2030

Epigenetics Drugs & Diagnostic Technologies Market, by Type (Epigenetic Drugs, (DNMT Inhibitors, HDAC Inhibitors and Others) and Epigenetics Diagnostic Technologies and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: | 出版商: Coherent Market Insights | 英文 149 Pages | 商品交期: 2-3个工作天内

价格
简介目录

表观遗传学是一门以化学方式改变生物体内特定基因的学科。 表观遗传学药物用于逆转导致多种疾病的基因表达异常,包括癌症、心脏病、糖尿病和精神疾病。 癌症患病率的上升、生物技术行业投资的增加以及新药分子研发的增加预计将在预测期内推动市场增长。

市场动态

预计癌症患病率的增加将推动预测期内的市场增长。

根据世界卫生组织的数据,癌症是全球死亡的主要原因,2020 年约有 1000 万人死于癌症。 乳腺癌(226万例)、肺癌(221万例)和结直肠癌(193万例)的癌症新发病例数最多。

表观遗传改变通常与所有人类癌症相关,并且通常是导致癌症表型的遗传改变的原因。 表观遗传改变包括组蛋白修饰剂和阅读器、脱氧核糖核酸 (DNA) 甲基化、染色质重塑剂和染色质的其他成分。 表观遗传变化可导致基因突变,最终导致表观基因组变化。

表观遗传药物的作用是帮助逆转这些表观遗传变化。 表观遗传疗法通常用于治疗实体瘤和其他癌症。

这项研究的主要特点

  • 本报告以2021年为基准年,分析了预测期内(2022-2030年)的全球表观遗传药物和诊断技术市场、市场规模(百万美元)和復合年增长率(CAGR%)细节。
  • 解释了不同细分市场的潜在创收机会,并描述了针对该市场的有吸引力的投资建议矩阵。
  • 它还提供了有关市场驱动因素、制约因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
  • 根据公司亮点、产品组合、主要亮点、财务业绩和战略等参数介绍全球表观遗传学製药和诊断技术市场主要参与者的概况。
  • 本研究涉及的主要公司有:Regenacy Pharmaceuticals, Inc.、Astex Pharmaceuticals、4SC AG、CellCentric Ltd.、Celleron Therapeutics Ltd.、Bristol-Myers Squibb Company、Oryzon Genomics S.A.、ChromaMedicine, Inc.、Epizyme , Inc. 和 EpiGentek Group Inc.
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 《全球表观遗传学药物和诊断技术市场》报告面向该行业的各种利益相关者,包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者将能够通过用于分析全球表观遗传药物和诊断技术市场的各种战略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第二章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 市场细分:按类型
    • 按地区划分的市场细分
  • 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

  • 司机
  • 约束因素
  • 商机
  • 影响分析
  • 主要亮点
  • 产品发布和批准
  • 害虫分析
  • 技术进步
  • 监管场景
  • 併购、合作

第 4 章表观遗传学药物和诊断技术的全球市场:冠状病毒 (COVID-19) 大流行的影响

  • 经济影响
  • COVID-19 的流行病学特征
  • 对錶观遗传学和诊断试剂供需的影响

第 5 章表观遗传药物和诊断的全球市场:按类型,2017-2030

  • 表观遗传药物
  • DNMT抑製剂
  • HDAC 抑製剂
  • 其他
  • 表观遗传学诊断技术
  • DNA甲基化
  • 芯片技术

第 6 章 2017 年至 2030 年按地区分列的全球表观遗传学和诊断市场

  • 北美
  • 美国
  • 加拿大
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲地区
  • 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲地区
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 韩国
  • 东盟
  • 其他亚太地区
  • 中东
  • 海湾合作委员会
  • 以色列
  • 其他中东地区
  • 非洲
  • 南非
  • 中非
  • 北非

第七章竞争格局

  • 竞争快照
    • Regenacy Pharmaceuticals, Inc.
    • Astex Pharmaceuticals
    • 4SC AG
    • CellCentric Ltd.
    • Celleron Therapeutics Ltd.
    • Bristol-Myers Squibb Company
    • Oryzon Genomics S.A.
    • ChromaMedicine, Inc.
    • Epizyme, Inc.
    • EpiGentek Group Inc.

第 8 章

  • 参考文献
  • 调查方法
简介目录
Product Code: CMI4026

Epigenetics is the study of chemical modifications of some specific genes of an organism. Epigenetic drugs are used to reverse the abnormal gene expression which leads to different types of diseases such as cancer, heart disease, diabetes, and mental illnesses. Increasing prevalence of cancer, increasing research and development for new drug molecule along with increasing investment in biotechnology industry is expected to propel market growth during the forecasted period.

Market Dynamics

Increasing prevalence of cancer is expected to drive the market growth during the forecast period.

According to the World Health Organization, cancer is a leading cause of death worldwide, which accounted for around 10 million deaths in 2020. The most common cancer, in terms of new cases of cancer were breast (2.26 million cases), lung (2.21 million cases) and colon & rectum (1.93 million cases).

Epigenetic changes are commonly associated with all human cancers and often responsible for genetic alterations driving the cancer phenotype. The changes includes histone modifiers and readers, Deoxyribonucleic acid (DNA) methylation, chromatin remodelers, and other components of chromatin. The epigenetic changes can lead to mutations in genes which eventually causes modification of the epigenome.

The function of epigenetic drugs in that they help in reversing these epigenetic changes. Epigenetic therapies are often used in the treatment of solid tumors and other types of cancer.

Key features of the study:

  • This report provides an in-depth analysis of the global epigenetics drugs & diagnostic technologies market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global epigenetics drugs & diagnostic technologies market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Regenacy Pharmaceuticals, Inc., Astex Pharmaceuticals, 4SC AG, CellCentric Ltd., Celleron Therapeutics Ltd., Bristol-Myers Squibb Company, Oryzon Genomics S.A., ChromaMedicine, Inc., Epizyme, Inc., and EpiGentek Group Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global epigenetics drugs & diagnostic technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epigenetics drugs & diagnostic technologies market

Detailed Segmentation:

  • Global Epigenetics Drugs & Diagnostic Technologies Market, By Type:
    • Epigenetic Drugs
      • DNMT Inhibitors
      • Azacitidine
      • Decitabine
      • HDAC Inhibitors
      • Vorinostat
      • Romidepsin
      • Others
    • Epigenetics Diagnostic Technologies
      • DNAMethylation
      • CHIP Technology
  • Global Epigenetics Drugs & Diagnostic Technologies Market, By Region:
    • North America
      • By Country
    • U.S.
    • Canada
    • Latin America
      • By Country
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
      • By Country
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
      • By Country
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
      • By Country
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
      • By Country/Region
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Regenacy Pharmaceuticals, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Astex Pharmaceuticals
    • 4SC AG
    • CellCentric Ltd.
    • Celleron Therapeutics Ltd.
    • Bristol-Myers Squibb Company
    • Oryzon Genomics S.A.
    • ChromaMedicine, Inc.
    • Epizyme, Inc.
    • EpiGentek Group Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Drivers
  • Restraints
  • Opportunity
  • Impact Analysis
  • Key Highlights
  • Product Launch/Approvals
  • PEST Analysis
  • Technological Advancements
  • Regulatory Scenario
  • Mergers, Acquisitions and Collaborations

4. Global Epigenetic Drugs & Diagnostic Technologies Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand of Epigenetics Drugs & Diagnostic Products

5. Global Epigenetic Drugs & Diagnostic Technologies Market, By Type, 2017 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, 2017 - 2030
    • Segment Trends
  • Epigenetic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • DNMT Inhibitors
    • Azacitidine
    • Decitabine
  • HDAC Inhibitors
    • Vorinostat
    • Romidepsin
  • Others
  • Epigenetics Diagnostic Technologies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
  • DNAMethylation
  • CHIP Technology

6. Global Epigenetic Drugs & Diagnostic Technologies Market, By Region, 2017 - 2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • North America
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Type, 2017 - 2030, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
  • South Africa
  • Central Africa
  • North Africa

7. Competitive Landscape

  • Competitive Snapshot
    • Regenacy Pharmaceuticals, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Astex Pharmaceuticals
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • 4SC AG
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • CellCentric Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Celleron Therapeutics Ltd.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Bristol-Myers Squibb Company
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Oryzon Genomics S.A.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • ChromaMedicine, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • Epizyme, Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies
    • EpiGentek Group Inc.
  • Company Overview
  • Product Portfolio
  • Financial Overview
  • Key Highlights
  • Market Strategies

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact